Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: A nationwide survey in Japan

Blood

Volumn 108, Issue 1, 2006, Pages 382-389

  Kim, Sung Won ^b   Tanimoto, Tetsuya E ^b   Hirabayashi, Noriyuki ^b   Goto, Seiichi ^b   Kami, Masahiro ^b   Yoshioka, Satoshi ^b   Uchida, Toshiki ^b   Kishi, Kenji ^b   Tanaka, Yuji ^b   Kohno, Akio ^b   Kasai, Masaharu ^b   Higuchi, Masakazu ^b   Kasai, Masanobu ^b   Mori, Shin Ichiro ^b   Fukuda, Takahiro ^b   Izutsu, Koji ^b   Sao, Hiroshi ^b   Ishikawa, Takayuki ^b   Ichinohe, Tatsuo ^b   Takeuchi, Kengo ^b   Tajima, Kinuko ^b   Tanosaki, Ryuji ^b   Harada, Mine ^b   Taniguchi, Shuichi ^b   Tobinai, Kensei ^b   Hotta, Tomomitsu ^b   Takaue, Yoichi ^a   more..

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND;

ADOLESCENT; ADULT; AGED; CHILD; DEMOGRAPHY; DISEASE CLASSIFICATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 33745627072     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-02-0596     Document Type: Review

References (34)

1. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
2. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004;350:1287-1295.
3. Horning SJ, Negrin RS, Hoppe RT, et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood. 2001;97:404-409.
4. Dhedin N, Giraudier S, Gaulard P, et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Br J Haematol. 1999;107:154-161.
5. van Besien KW, Mehra RC, Giralt SA, et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med. 1996;100:299-307.
6. van Besien K, Thall P, Korbling M, et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997;3:150-156.
7. van Besien K, Sobocinski KA, Rowlings PA, et al. Allogeneic bone marrow transplantation for lowgrade lymphoma. Blood. 1998;92:1832-1836.
8. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667-678.
9. Levine JE, Harris RE, Loberiza FR Jr, et al. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003;101:2476-2482.
10. van Besien K, Loberiza FR Jr, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102:3521-3529.
11. Forrest DL, Thompson K, Nevill TJ, Couban S, Fernandez LA. Allogeneic hematopoietic stem cell transplantation for progressive follicular lymphoma. Bone Marrow Transplant. 2002;29:973-978.
12. Berdeja JG, Jones RJ, Zahurak ML, et al. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transplant. 2001;7:561-567.
13. Stein RS, Greer JP, Goodman S, et al. Limited efficacy of intensified preparative regimens and autologous transplantation as salvage therapy in high-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;40:521-528.
14. Khouri IF, Lee MS, Romaguera J, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999;10:1293-1299.
15. Zaja F, Russo D, Silvestri F, et al. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome. Haematologica. 1997;82:171-177.
16. Makita M, Maeda Y, Takenaka K, et al. Successful treatment of progressive NK cell lymphoma with allogeneic peripheral stem cell transplantation followed by early cyclosporine tapering and donor leukocyte infusions. Int J Hematol. 2002;76:94-97.
17. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21:4407-4412.
18. Khouri IF, Saliba RM, Giralt SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595-3599.
19. Tanimoto TE, Kusumi E, Hamaki T, et al. High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. Bone Marrow Transplant. 2003;32:131-137.
20. Bierman PJ. Allogeneic bone marrow transplantation for lymphoma. Blood Rev. 2000;14:1-13.
21. Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
22. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
23. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204-217.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;457-481.
25. Akpek G, Ambinder RF, Piantadosi S, et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol. 2001;19:4314-4321.
26. Bortin MM, Kay HE, Gale RP, Rimm AA. Factors associated with interstitial pneumonitis after bone-marrow transplantation for acute leukaemia. Lancet. 1982;1:437-439.
27. Weiner RS, Bortin MM, Gale RP, et al. Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med. 1986;104:168-175.
28. Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood. 1994;84:1050-1055.
29. Chopra R, Goldstone AH, Pearce R, et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol. 1992;10:1690-1695.
30. Freytes CO, Loberiza FR, Rizzo JD, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004;104:3797-3803.
31. Izutsu K, Kanda Y, Ohno H, et al. Unrelated bone marrow transplantation for non-Hodgkin lymphoma: a study from the Japan Marrow Donor Program. Blood. 2004;103:1955-1960.
32. Yanada M, Emi N, Naoe T, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant. 2004;34:331-337.
33. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857-864.
34. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468-476.